Rosanne M Crooke

Summary

Affiliation: Isis Pharmaceuticals
Country: USA

Publications

  1. doi request reprint Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice
    Esther Merki
    University of California San Diego, La Jolla, CA 92093 0682, USA
    Circulation 118:743-53. 2008
  2. ncbi request reprint Metabolism of antisense oligonucleotides in rat liver homogenates
    R M Crooke
    Isis Pharmaceuticals, Inc, Carlsbad Research Center, Carlsbad, CA 92008, USA
    J Pharmacol Exp Ther 292:140-9. 2000
  3. ncbi request reprint An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
    Rosanne M Crooke
    Cardiovascular Group, Antisense Drug Discovery, Isis Pharmaceuticals, Inc, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    J Lipid Res 46:872-84. 2005
  4. ncbi request reprint Antisense oligonucleotides as therapeutics for hyperlipidaemias
    Rosanne M Crooke
    Isis Pharmaceuticals, Inc, 1896 Rutherford Avenue, Carlsbad, CA 92008, USA
    Expert Opin Biol Ther 5:907-17. 2005
  5. pmc Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein
    Richard G Lee
    Cardiovascular Antisense Drug Discovery Group, Isis Pharmaceuticals, Carlsbad, CA 92010, USA
    J Lipid Res 54:602-14. 2013
  6. pmc Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice
    Adam E Mullick
    Isis Pharmaceuticals, Inc, Carlsbad, CA, USA
    J Lipid Res 52:885-96. 2011
  7. doi request reprint Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans
    Mark J Graham
    Isis Pharmaceuticals, Carlsbad, CA 92010, USA
    Circ Res 112:1479-90. 2013
  8. pmc Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice
    Thomas A Bell
    Cardiovascular Antisense Drug Discovery Group, Isis Pharmaceuticals, Inc, Carlsbad, CA 92010
    J Lipid Res 54:2647-57. 2013
  9. doi request reprint Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
    Rosie Z Yu
    Primary Laboratory of Origin, Isis Pharmaceuticals, Inc, 1896 Rutherford Road, Carlsbad, CA 92008, USA
    Biochem Pharmacol 77:910-9. 2009
  10. ncbi request reprint Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
    Mark J Graham
    Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc, Carlsbad, CA 92008, USA
    J Lipid Res 48:763-7. 2007

Collaborators

  • Stanley T Crooke
  • M J Graham
  • Adam E Mullick
  • Richard S Geary
  • R Z Yu
  • John J P Kastelein
  • LOREN FONG
  • Lawrence Rudel
  • Henry Ginsberg
  • Laura Liscum
  • S Tsimikas
  • Thomas A Bell
  • Richard G Lee
  • J Mark Brown
  • Wuxia Fu
  • Esther Merki
  • Victoria M Rimkunas
  • Yumi Imai
  • Yuan Li Zhang
  • Anh T Nguyen
  • María González Ferreiro
  • Donna Sipe
  • Dan Norris
  • Danielle Gattis
  • Sheri Booten
  • Heather M Alger
  • Ramesh Shah
  • Matthew A Davis
  • Thomas L Smith
  • Martha D Wilson
  • Janet K Sawyer
  • Robert E Pitas
  • Kathryn Kelley
  • Elizabeth R Miller
  • Joseph L Witztum
  • Gladys M Varela
  • Rexford S Ahima
  • Malaka B Jackson
  • Sylvie Braschi
  • Patty Siri
  • Li Shin Huang
  • Antonio Hernandez-Ono
  • Ross Milne
  • Michèle Geoffrion
  • Kristina M Lemonidis
  • Stuart Weisberg
  • Stephen G Young
  • Donna Conlon
  • Gregory Hardee
  • Lloyd Tillman
  • Roland Bodmeier

Detail Information

Publications19

  1. doi request reprint Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice
    Esther Merki
    University of California San Diego, La Jolla, CA 92093 0682, USA
    Circulation 118:743-53. 2008
    ..Lipoprotein (a) [Lp(a)] is a genetic cardiovascular risk factor that preferentially binds oxidized phospholipids (OxPL) in plasma. There is a lack of therapeutic agents that reduce plasma Lp(a) levels...
  2. ncbi request reprint Metabolism of antisense oligonucleotides in rat liver homogenates
    R M Crooke
    Isis Pharmaceuticals, Inc, Carlsbad Research Center, Carlsbad, CA 92008, USA
    J Pharmacol Exp Ther 292:140-9. 2000
    ....
  3. ncbi request reprint An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
    Rosanne M Crooke
    Cardiovascular Group, Antisense Drug Discovery, Isis Pharmaceuticals, Inc, 2292 Faraday Avenue, Carlsbad, CA 92008, USA
    J Lipid Res 46:872-84. 2005
    ....
  4. ncbi request reprint Antisense oligonucleotides as therapeutics for hyperlipidaemias
    Rosanne M Crooke
    Isis Pharmaceuticals, Inc, 1896 Rutherford Avenue, Carlsbad, CA 92008, USA
    Expert Opin Biol Ther 5:907-17. 2005
    ..This article describes the antisense technology platform, highlights the advantages of these novel drugs for the treatment of hyperlipidaemia and reviews the current research in this area...
  5. pmc Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein
    Richard G Lee
    Cardiovascular Antisense Drug Discovery Group, Isis Pharmaceuticals, Carlsbad, CA 92010, USA
    J Lipid Res 54:602-14. 2013
    ..Thus, although both drugs effectively lowered LDL-C levels in mice, the apoB ASO produced a more positive liver safety profile...
  6. pmc Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice
    Adam E Mullick
    Isis Pharmaceuticals, Inc, Carlsbad, CA, USA
    J Lipid Res 52:885-96. 2011
    ....
  7. doi request reprint Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans
    Mark J Graham
    Isis Pharmaceuticals, Carlsbad, CA 92010, USA
    Circ Res 112:1479-90. 2013
    ..Furthermore, elevated apoC-III levels have been associated with metabolic syndrome and type 2 diabetes mellitus. To date, no selective apoC-III therapeutic agent has been evaluated in the clinic...
  8. pmc Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice
    Thomas A Bell
    Cardiovascular Antisense Drug Discovery Group, Isis Pharmaceuticals, Inc, Carlsbad, CA 92010
    J Lipid Res 54:2647-57. 2013
    ..These preliminary findings suggest that CETP ASOs may represent an alternative means to inhibit that target and to support their continued development as a treatment for cardiovascular disease in man. ..
  9. doi request reprint Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
    Rosie Z Yu
    Primary Laboratory of Origin, Isis Pharmaceuticals, Inc, 1896 Rutherford Road, Carlsbad, CA 92008, USA
    Biochem Pharmacol 77:910-9. 2009
    ..The cross-species PK/PD relationships provide confidence in the use of pharmacology animal models to predict human dosing for second-generation ASOs targeting the liver...
  10. ncbi request reprint Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
    Mark J Graham
    Cardiovascular Group, Department of Antisense Drug Discovery, Isis Pharmaceuticals, Inc, Carlsbad, CA 92008, USA
    J Lipid Res 48:763-7. 2007
    ..Antisense inhibition of PCSK9 is an attractive and novel therapeutic approach for treating hypercholesterolemia in human...
  11. doi request reprint Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology
    Rosanne M Crooke
    Cardiovascular Disease Research, Antisense Drug Discovery, Isis Pharmaceuticals, Carlsbad, CA, USA
    Methods Mol Biol 1027:309-24. 2013
    ....
  12. pmc Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss
    J Mark Brown
    Department of Pathology, Biochemistry, and Orthopedic Surgery, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1040, USA
    J Biol Chem 283:10522-34. 2008
    ..Collectively, these studies provide the first insight into the hepatic itinerary of cholesterol when cholesterol esterification is inhibited only in the liver, and provide evidence for a novel non-biliary route of fecal sterol loss...
  13. pmc In vivo antisense oligonucleotide reduction of NPC1 expression as a novel mouse model for Niemann Pick type C- associated liver disease
    Victoria M Rimkunas
    Department of Physiology, Tufts University School of Medicine, Boston, MA 02111, USA
    Hepatology 47:1504-12. 2008
    ..CONCLUSION: This novel NPC1 antisense mouse model will allow delineation of the mechanism by which NPC1 dysfunction leads to liver cell death...
  14. ncbi request reprint Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis
    Yuan Li Zhang
    Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    J Biol Chem 281:37603-15. 2006
    ..The mechanism whereby hepatic Ppargamma2 gene expression is increased and how PPARgamma2 stimulates lipogenesis is under investigation...
  15. ncbi request reprint Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice
    Thomas A Bell
    Department of Pathology, Section on Lipid Sciences, Wake Forest University Health Sciences, Medical Center Blvd, Winston Salem, NC 27157, USA
    Arterioscler Thromb Vasc Biol 26:1814-20. 2006
    ..The purpose of this study was to determine the effects of liver-specific inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) on the development of hypercholesterolemia and atherosclerosis in mice...
  16. ncbi request reprint Reduction of hepatosteatosis and lipid levels by an adipose differentiation-related protein antisense oligonucleotide
    Yumi Imai
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19010, USA
    Gastroenterology 132:1947-54. 2007
    ..We postulated that a reduction in ADRP would ameliorate hepatic steatosis and improve insulin action...
  17. ncbi request reprint Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
    John J P Kastelein
    Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, PO Box 22700, Room F4 159 2, 1100 DE Amsterdam, The Netherlands
    Circulation 114:1729-35. 2006
    ..In the present study, we describe the outcome of the first-in-humans study on the safety and efficacy of an antisense oligonucleotide inhibitor of apoB...
  18. ncbi request reprint A mouse monoclonal antibody specific for mouse apoB48 and apoB100 produced by immunizing "apoB39-only" mice with mouse apoB48
    Anh T Nguyen
    Lipoprotein and Atherosclerosis Research Group, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, ON, Canada K1Y 4W7
    Biochim Biophys Acta 1761:182-5. 2006
    ..The antibody will be an important reagent for studying mouse models of atherosclerosis. The study also underscores the utility of genetically modified mice for generating mouse mAbs against mouse proteins...
  19. ncbi request reprint Stability of polycationic complexes of an antisense oligonucleotide in rat small intestine homogenates
    María González Ferreiro
    College of Pharmacy, Freie Universitat Berlin, Berlin, Germany
    Eur J Pharm Biopharm 55:19-26. 2003
    ..The association of oligonucleotides with several polycationic substances proved to be an alternative to chemical modification in order to stabilize oligonucleotides in the gastrointestinal tract against nucleolytic degradation...